Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

A professional discussion on diagnosing type 1 diabetes based on autoimmune antibodies, oral glucose tolerance test results, fasting glucose, and hemoglobin A1C levels.

EP: 1.Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

EP: 2.Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

EP: 3.Identifying Risk to Enable Early Detection of Type 1 Diabetes

EP: 4.Challenges in Autoantibody Screening for Type 1 Diabetes

EP: 5.Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

Now Viewing

EP: 6.Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

EP: 7.Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Related Videos

Related Content

Advertisement

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

Related Content

Advertisement

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.